🧪 This Bladder Cancer Awareness Month, discover STARBURST 1 (EORTC-2418), advancing precision research in muscle-invasive bladder cancer under the SPECTA platform. Many thanks to the supporters contributing to this important research. #EORTCgenitourinary #BladderCancer

EORTC GUCG 2238 – DE-ESCALATE: A pragmatic trial to revisit intermittent ADT in #mHSPC in the era of new ARPIs. Presentation by @fabioturco92. #ASCO26 written coverage by @zklaassen_md > bit.ly/4veWaVI @ASCO

DE-ESCALATE (@EORTC): A pragmatic trial to revisit intermittent ADT in mHSPC in the era of new ARPIs @urotoday #ASCO26 🌟n=1,600 🌟Key elig criteria: mHSPC pts, PSA ≤ 0.2 at 6-12 mos after Rx start 🌟2:1 randomization to cMAB vs iMAB 🌟Co-primary EPs: (i) feasibility (ii) overall survival 🌟Status: May 1, 2026: 211 pts enrolled

EORTC GUCG 2238 de-escalate: A pragmatic trial to revisit intermittent ADT in metastatic hormone-naïve #ProstateCancer in the era of new AR pathway inhibitors. Presentation by @GGrisay. #ESMO25 written coverage by @zklaassen_md > bit.ly/4qj2uda @myESMO

🌟Challenges in Defining Clinical CR to Systemic Therapy in MIBC🌟 @EORTC #STARBURST project 🖋️ Alexandra Masson-Lecomte @AFUrology, Guillaume Grisay, @vandamme_jvd,  @Achard_Verane  , @LAUrology_NL, @robert_huddart, @frasor86, @LDyrskjot, Yves Allory @institut_curie, @BertrandTOMBAL, @VPanebiancoIT, @y_loriot. @OncoAlert @EUplatinum sciencedirect.com/science/ar… 🔸 Clinical CR ≠ Pathologic CR — current methods often fail to predict true response 🔸 STARBURST trial aims to refine cCR definition via:   • Multiparametric MRI   • Cystoscopy urine cytology   • ctDNA (plasma & urine)   • Urinary biomarkers 🔸 Goal: tailor organ-sparing strategies and avoid overtreatment 🔸 Collaborative European effort to shape the future of MIBC response assessment #BladderCancer #MIBC #Immunotherapy #ctDNA #PrecisionMedicine #EORTC #UroOncology #ClinicalTrials #CRvspCR #OrganPreservation #Cancer #Oncology #MedX

🚨 Defining clinical response to neoadjuvant CT in bladder is crucial to offer bladder-sparing strategies in complete or near cplt responders ! EORTC Starbust-1 will launch soon @amassonlecomte @EORTC @y_loriot @BertrandTOMBAL @Achard_Verane @vandamme_jvd sciencedirect.com/science/ar…

Check out our free 20-minute webinar with a multidisciplinary panel of experts discussing the most recent data from clinical trials, treatment (de)escalation, and the role of ultra-low PSA in #mHSPC Register for free at library.mirrorsmed.org/?utm_… @vandamme_jvd @OncoAlert #GU #ProstateCancer

Thank you #EMUC24 for giving me the opportunity to talk about the management of mCRPC patients

mHSPC patient with profound PSA response : panel would propose de-escalation therapy ! #EMUC2024 @BertrandTOMBAL @Silke_Gillessen @fabioturco92

Nice talk by Dr Masson-Lecomte on the importance of defining the response to NAT, as well as the importance of multimodal assessment. Question will be answered by the EORTC2418 - ‘STARBURST’ study !#EORTC #EMUC24 @y_loriot @Achard_Verane @vandamme_jvd @GGrisay @BertrandTOMBAL

Congrats to @vandamme_jvd @GIZZIMarcoMd for this nice poster #EMUC24 @BertrandTOMBAL

#NOVEMBREAUMASCULIN - Conférence de presse en cours pour présenter cette 2e édition du Mois de la Santé Masculine 🔵 @delataillealex #Santemasculine #BrisonsLesTabous 🚹

OH LA PHOTO

🚨 Excellent talk on germline testing in PC by Heather H. Cheng🚨 ✅ It matters for patients AND families ✅ Germline alt. are FREQUENT and have consequences for patients 🧬Tumor-only sequencing failed to detect > 20% of pathogenic variants ⚠ @APCCC_Lugano @OncoAlert #APCCC24

95% of @APCCC_Lugano Panellists DO NOT recommend ARPI switch for mCRPC. Yet why do investigators (many of them Panellists) and FDA approve this as control arm for trials?? “Unethical” says @AnthonyMJoshua from the floor, as did @VPrasadMDMPH on GU Cast @gu_onc #APCCC24

🤔 How to choose a 1st line therapy in mCRPC patients nowadays ? 🚨 ➤ Some excellent suggestions from @ChrisSweens1 at @APCCC_Lugano @OncoAlert #APCCC24